Frazier Life Sciences Management L.P. Takes $3.79 Million Position in Xilio Therapeutics, Inc. $XLO

Frazier Life Sciences Management L.P. purchased a new stake in shares of Xilio Therapeutics, Inc. (NASDAQ:XLO) during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 5,915,091 shares of the company’s stock, valued at approximately $3,787,000. Frazier Life Sciences Management L.P. owned approximately 0.09% of Xilio Therapeutics at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in the company. State Street Corp boosted its stake in shares of Xilio Therapeutics by 13.7% during the fourth quarter. State Street Corp now owns 186,390 shares of the company’s stock valued at $119,000 after purchasing an additional 22,500 shares in the last quarter. Jane Street Group LLC acquired a new stake in shares of Xilio Therapeutics during the fourth quarter valued at about $27,000. Squarepoint Ops LLC boosted its stake in shares of Xilio Therapeutics by 39.6% during the third quarter. Squarepoint Ops LLC now owns 328,794 shares of the company’s stock valued at $277,000 after purchasing an additional 93,338 shares in the last quarter. Renaissance Technologies LLC boosted its stake in shares of Xilio Therapeutics by 68.3% during the fourth quarter. Renaissance Technologies LLC now owns 344,416 shares of the company’s stock valued at $220,000 after purchasing an additional 139,716 shares in the last quarter. Finally, Velan Capital Investment Management LP acquired a new stake in shares of Xilio Therapeutics during the fourth quarter valued at about $109,000. 54.29% of the stock is owned by institutional investors and hedge funds.

Xilio Therapeutics Price Performance

Xilio Therapeutics stock opened at $8.31 on Friday. The stock’s 50 day moving average is $8.23 and its 200 day moving average is $8.55. The firm has a market cap of $54.68 million, a P/E ratio of -2.34 and a beta of -0.12. Xilio Therapeutics, Inc. has a one year low of $6.47 and a one year high of $12.74.

Xilio Therapeutics (NASDAQ:XLO) last posted its quarterly earnings data on Tuesday, May 12th. The company reported ($0.58) EPS for the quarter, topping analysts’ consensus estimates of ($0.66) by $0.08. The company had revenue of $12.65 million for the quarter, compared to analyst estimates of $8.52 million. Xilio Therapeutics had a negative return on equity of 151.42% and a negative net margin of 58.52%.

Analysts Set New Price Targets

A number of analysts have recently commented on XLO shares. Weiss Ratings lowered Xilio Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, May 26th. Wall Street Zen lowered Xilio Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday, May 16th. One equities research analyst has rated the stock with a Strong Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Xilio Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $28.00.

About Xilio Therapeutics

Xilio Therapeutics is a clinical‐stage biotechnology company focused on the discovery and development of tumor‐targeted cytokine therapeutics for the treatment of cancer. The company leverages a proprietary platform to design pro‐drug versions of potent immune‐modulating cytokines, enabling local activation of immune responses within the tumor microenvironment while limiting systemic exposure and toxicity.

The company’s lead programs utilize engineered interleukin‐12 (IL‐12) and interleukin‐2 (IL‐2) molecules fused to tumor‐binding antibodies or peptide ligands.